Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (471-480 of 551) with videos related to

Pageof 56
Sort By:
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Open Forum Infectious Diseases|November 29, 2023
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021Kathryn E Stephenson, Jasmine R Marcelin, Audrey E Pettifor, et al.
Pharmaceutics|May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIVBryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Journal of the International AIDS Society|June 4, 2025
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical dataShelly Karuna, Fatima Laher, Sufia Dadabhai, et al.
Statistical Communications in Infectious Diseases|December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B Gilbert, Michal Juraska, Allan C deCamp, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Iscience|April 22, 2026
Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humansDaniel J Schuster, Shuying S Li, Dieter Mielke, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
Pageof 56

Showing results (471-480 of 551) with videos related to

Sort By:
Pageof 56
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Open Forum Infectious Diseases|November 29, 2023
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021Kathryn E Stephenson, Jasmine R Marcelin, Audrey E Pettifor, et al.
Pharmaceutics|May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIVBryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Journal of the International AIDS Society|June 4, 2025
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical dataShelly Karuna, Fatima Laher, Sufia Dadabhai, et al.
Statistical Communications in Infectious Diseases|December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B Gilbert, Michal Juraska, Allan C deCamp, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Iscience|April 22, 2026
Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humansDaniel J Schuster, Shuying S Li, Dieter Mielke, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
Pageof 56